secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001104659-22-041035
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Therapeutics appoints Asif Ali as EVP, CFO effective April 18, 2022
-------------------------------------------------------------------------------

- Asif Ali, 48, appointed EVP, CFO; previously VP Finance & CAO at Theravance Biopharma (2018-2022) and VP Corp Controller at Depomed.
- Annual base salary $425,000; eligible for discretionary bonus up to 40% of base salary.
- Initial equity grant: option to purchase 82,500 shares (4-yr vest, 1-yr cliff) and 13,750 RSUs (4-yr equal installments).
- No family relationships with any executive officer or director; no material interests in reportable transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922041035/0001104659-22-041035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922041035/tm2210916d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-041035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer